Immunogenomics of Cholangiocarcinoma

The immunogenomics of cholangiocarcinoma (CCA) is a rapidly evolving field that explores the interplay between genetic and non-genetic alterations in tumor cells and immune cells, and their impact on antitumor immunity, tumor progression, and response to therapy. Below is a detailed overview of key aspects related to immunogenomics in CCA:

### 1. **Understanding Immunogenomics in CCA**

• **Definition**: Immunogenomics investigates how mutations, chromosomal instability (CIN), and epigenetic changes in tumor cells or immune cells shape the immune microenvironment and influence the immune system's ability to recognize and attack tumors.
• **Relevance**: In CCA, this approach is critical due to its highly heterogeneous nature, with distinct genetic profiles and immune landscapes in different anatomical subtypes (intrahepatic CCA [iCCA] and extrahepatic CCA [eCCA]).

### 2. **Genomic Alterations Influencing Immunity**

• **Tumor Mutational Burden (TMB)**: High TMB is associated with increased production of neoantigens, which can enhance immune recognition. However, TMB is generally low in CCA, limiting its immunogenic potential.
• **Microsatellite Instability-High (MSI-H) and DNA Mismatch Repair Deficiency (dMMR)**: These features are strong predictors of immune responsiveness in cancers. In CCA, MSI-H occurs in only 1–5% of cases, but when present, it can make tumors more susceptible to immunotherapies like immune checkpoint inhibitors.
• **Chromosomal Instability (CIN)**: CIN activates the cGAS–STING pathway, leading to inflammation and the creation of a tumor-supportive microenvironment. This is mediated by IL-6, which promotes immune suppression and tumor progression.

### 3. **Driver Mutations and Neoantigens**

• **Key Mutations**: Common oncogenic drivers in CCA include IDH1/2, FGFR2, KRAS, TP53, BAP1, and ARID1A. These mutations influence tumor biology and immune evasion differently across iCCA and eCCA subtypes.
• **Stable Neoantigens**: Certain mutations, such as KRAS^G12D^, produce stable neoantigens that are less prone to immune editing, making them promising targets for immunotherapies like vaccines or engineered T cells.
• **Alternative Neoantigens**: Aberrant expression of olfactory receptors or altered mucin glycosylation patterns can generate non-mutational neoantigens, which may be leveraged for personalized vaccine or CAR-T cell therapies.

### 4. **Immune Microenvironment in CCA**

• **Immune Subtypes**: CCA can be classified into three immune microenvironment subtypes:
• **Immune Desert**: Characterized by low immune cell infiltration, leading to poor immunotherapy response.
• **Immune Excluded**: Immune cells are present but excluded from the tumor core, limiting their antitumor activity.
• **Inflamed**: High immune cell infiltration, often associated with better immunotherapy response but also immune suppression due to chronic inflammation.
• **T Cell Dysfunction**: Chronic antigen exposure or infection leads to T cell exhaustion, reducing their ability to fight tumors. This is particularly evident in KRAS-mutant inflammatory iCCA.
• **Cytokine Crosstalk**: Tumor-associated macrophages (TAMs) release cytokines like IL-10 and TGF-β, promoting epithelial–mesenchymal transition (EMT), immune suppression, and tumor progression.

### 5. **BRCA Mutations and Immunogenicity**

• **BRCA1/2 Alterations**: These mutations are rare in CCA (~3.6%) but increase DNA damage and inflammatory signaling. They are associated with higher TMB and enhanced immunogenic potential, making BRCA-mutant tumors more likely to respond to immune-based therapies.

### 6. **Immune Checkpoints and Therapeutic Targets**

• **Checkpoint Overexpression**: Immune checkpoints such as PD-1, CTLA-4, and GITR are often overexpressed in tumor-infiltrating lymphocytes in CCA, making them key targets for immune checkpoint blockade therapies.
• **Combination Therapies**: Combining immune checkpoint inhibitors (e.g., anti–PD-1/PD-L1) with IL-6R or VEGFR inhibitors shows promise in enhancing immune responses by targeting multiple steps in the cancer-immunity cycle.

### 7. **Emerging Immunotherapeutic Strategies**

• **Personalized Vaccines**: A case study demonstrated long-term remission in metastatic iCCA using a personalized peptide vaccine targeting expressed, non-mutated tumor peptides.
• **Adoptive Cell Therapies**: CAR-T cells and TCR-engineered T cells targeting tumor-specific or non-genetic antigens are being developed as strategies for resistant CCA subtypes.
• **Alternative Targets**: Aberrant mucin glycosylation and olfactory receptor expression may provide novel targets for vaccine or CAR-T development.

### 8. **Challenges in Immunogenomic Research**

• **Modeling Immune Evolution**: Studying immune dynamics in vivo is challenging due to species differences and the complexity of immune subpopulations.
• **Integration of Human Data**: Leveraging ex vivo human data is crucial to better understand immune evolution and improve therapeutic strategies.

### 9. **Clinical Implications**

• **Patient Stratification**: Immune-based stratification is expected to become a standard approach in CCA management, enabling tailored immunotherapeutic interventions based on genomic and immune profiles.
• **Future Directions**: Combining immunogenomics with genomic-guided therapies holds promise for improving survival outcomes in CCA patients.

### Conclusion

The immunogenomics of cholangiocarcinoma highlights the complex interplay between tumor genetics, immune microenvironment, and therapeutic response. By understanding these interactions, researchers and clinicians can develop more effective, personalized immunotherapies that address the unique challenges posed by this heterogeneous cancer type.